Edgar Filing: Tubridy Karen L - Form 4

Tubridy Kar	en L									
Form 4 March 05, 20)10									
	_							OMB A	PPROVAL	
FORM	14 UNITED ST		SECURITIES AND EXCHANGE CO Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWN				COMMISSION		3 3235-0287 ber:	
Check the if no long subject to	stateme						NERSHIP OF	Expires: Estimated a		
Section 1 Form 4 o		SECURITIES						burden hours per		
Form 5		ant to Section 1	6(a) of th	e Securiti	es Ex	chang	e Act of 1934.	response	0.5	
obligation may cont	ns Section 17(a)					-	f 1935 or Sectio	n		
See Instru 1(b).		30(h) of the In	vestment	Company	Act	of 194	40			
(Print or Type I	Responses)									
1. Name and A Tubridy Kar	Symbol	•				5. Relationship of Reporting Person(s) to Issuer				
		Akebia Therapeutics, Inc. [AKBA]				(Check all applicable)				
(Last)	(First) (Mid		f Earliest Tr	ansaction			D. (100		
C/O AKEBI		(Month/Day/Year) 02/28/2019				Director 10% Owner Officer (give title Other (specify				
INC., 245 F	, 02/20/2	02/20/2019				below) below) SVP, Chief Development Officer				
	(Street)	4 If Ame	ndment Da	te Original				-		
			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line)			
CAMBRID	GE, MA 02142						_X_ Form filed by 0 Form filed by N Person	One Reporting Pe More than One Re		
(City)	(State) (Zi	^{p)} Tabl	e I - Non-D	erivative S	ecurit	ies Aco	quired, Disposed of	f, or Beneficial	lly Owned	
1.Title of	2. Transaction Date		3.	4. Securit	ies Ac	quired	5. Amount of	6. Ownership	7. Nature of	
Security (Instr. 3)	(Month/Day/Year) I	Execution Date, if any	Transactio Code	on(A) or Dis (D)	sposed	of	Securities Beneficially	Form: Direct (D) or	Indirect Beneficial	
(11041-0)		(Month/Day/Year)	× /				Owned	Indirect (I)	Ownership	
							Following Reported	(Instr. 4)	(Instr. 4)	
					(A) or		Transaction(s)			
			Code V		(D)	Price	(Instr. 3 and 4)			
Common Stock	02/28/2019		А	30,000 (1)	А	\$0	61,399 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Tubridy Karen L - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to buy)	\$ 7.28	02/28/2019		A	45,000	<u>(3)</u>	02/28/2029	Common Stock	45,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
Tubridy Karen L C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET CAMBRIDGE, MA 02142			SVP, Chief Development Officer			
Signatures						
/s/ Nicole R. Hadas, attorney-in-fact for H Tubridy	Karen	()3/05/2019			
** Signature of Reporting Person			Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.
- (2) Includes 1,170 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018.
- (3) The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.